Physician profile
Rajeev Kulkarni
NPI 1598825085
$10,532.29
in general payments reported to CMS, 2019-2025
72 companies · $2,345 in 2025
The $2,345 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $113 · 2021: $1,012 · 2022: $1,440 · 2023: $2,340 · 2024: $2,601 · 2025: $2,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,007 · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,007.29 |
| Education | $278.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $971.23 | 2019-2025 | Kisqali |
| Pfizer INC. | $871.20 | 2019-2025 | |
| Emd Serono, INC. | $654.53 | 2021-2024 | Tepmetko |
| Astrazeneca Pharmaceuticals LP | $467.83 | 2019-2025 | Enhertu, Imfinzi |
| Daiichi Sankyo INC. | $467.68 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Janssen Biotech, INC. | $438.65 | 2021-2024 | Darzalex, Imbruvica, Tecvayli |
| Abbvie INC. | $436.29 | 2023-2025 | |
| Celgene Corporation | $399.92 | 2021-2025 | Reblozyl, Opdualag, Opdivo |
| E.R. Squibb & Sons, L.L.C. | $376.44 | 2019-2025 | Opdivo, Augtyro |
| Pharmacyclics LLC, An Abbvie Company | $361.50 | 2019-2023 | Imbruvica, Epkinly |
| Gilead Sciences, INC. | $276.83 | 2021-2025 | Trodelvy |
| Astellas Pharma US INC | $273.59 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Genzyme Corporation | $260.27 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $258.46 | 2022-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $248.11 | 2019-2025 |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $244.34 | 2019-2023 | Lumakras, Vectibix, Xgeva |
| Glaxosmithkline, LLC. | $224.19 | 2022-2025 | Ojjaara, Shingrix, Zejula |
| Eisai INC. | $219.48 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $211.97 | 2021-2025 | Keytruda, Reblozyl, Welireg |
| Ipsen Biopharmaceuticals, INC | $183.97 | 2024-2025 | Onivyde |
| Seagen INC. | $167.75 | 2021-2023 | Padcev |
| Incyte Corporation | $144.65 | 2021-2025 | Jakafi |
| Rigel Pharmaceuticals, INC. | $132.68 | 2019-2023 | Tavalisse, Rezlidhia |
| Jazz Pharmaceuticals INC. | $125.83 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.75 | 2022-2025 | Iclusig, Fruzaqla |
| Springworks Therapeutics, INC. | $118.32 | 2024-2025 | Ogsiveo |
| Aveo Pharmaceuticals, INC. | $112.65 | 2021-2025 | Fotivda |
| Alexion Pharmaceuticals, INC. | $105.87 | 2024-2025 | Ultomiris |
| Beigene USA, INC. | $105.00 | 2021-2024 | Brukinsa |
| Tersera Therapeutics LLC | $103.40 | 2021-2025 | Zoladex, Xermelo |
| Array Biopharma INC | $97.20 | 2020-2025 | Mektovi, Braftovi, Lorbrena |
| Adaptive Biotechnologies Corporation | $92.86 | 2024-2025 | Clonoseq |
| Stemline Therapeutics INC. | $90.96 | 2023-2025 | Orserdu, Elzonris |
| Genmab U.S., INC. | $75.67 | 2023-2024 | Tivdak, Epkinly |
| Genentech USA, INC. | $73.59 | 2023 | Polivy, Venclexta, Lunsumio |
| Tempus Ai, INC | $69.59 | 2024-2025 | Xt Cdx |
| Pharmaessentia USA Corporation | $66.57 | 2023-2025 | Besremi |
| Taiho Oncology, INC. | $61.83 | 2022-2024 | |
| Blueprint Medicines Corporation | $52.36 | 2024-2025 | Ayvakit |
| Exelixis INC. | $48.27 | 2023-2025 | Cabometyx |
| Foundation Medicine, INC. | $47.24 | 2019-2023 | |
| Servier Pharmaceuticals LLC | $41.20 | 2022-2023 | |
| Acceleron Pharma, INC. | $38.38 | 2020 | |
| Agios Pharmaceuticals, INC. | $35.46 | 2024-2025 | Pyrukynd |
| Karyopharm Therapeutics INC. | $34.22 | 2022-2023 | Xpovio |
| Pharmacosmos Therapeutics INC. | $32.18 | 2025 | Monoferric |
| Amneal Pharmaceuticals LLC | $30.63 | 2024 | Avastin |
| Sun Pharmaceutical Industries INC. | $29.03 | 2021-2023 | Odomzo, Yonsa |
| Deciphera Pharmaceuticals INC. | $28.96 | 2022-2023 | Qinlock |
| Lilly USA, LLC | $26.81 | 2023 | Verzenio, Retevmo, Jaypirca |
| Fresenius Kabi USA, LLC | $24.65 | 2023 | Stimufend |
| Janssen Scientific Affairs, LLC | $24.15 | 2019 | |
| Progenics Pharmaceuticals, INC. | $23.46 | 2025 | |
| Beone Medicines USA, INC. | $22.76 | 2025 | Tevimbra |
| Iovance Biotherapeutics, INC. | $22.38 | 2025 | Amtagvi |
| Azurity Pharmaceuticals, INC. | $20.59 | 2025 | Vivimusta, Danziten |
| Fennec Pharmaceuticals, INC. | $19.28 | 2024 | Pedmark |
| Spectrum Pharmaceuticals INC. | $18.92 | 2025 | Rolvedon |
| Cumberland Pharmaceuticals, INC. | $18.14 | 2024 | Sancuso |
| Apellis Pharmaceuticals, INC. | $17.55 | 2022 | |
| Kite Pharma, INC. | $17.14 | 2025 | Yescarta |
| Recordati_rare_diseases_inc. | $16.25 | 2025 | Enjaymo |
| Alnylam Pharmaceuticals INC. | $15.97 | 2024 | Givlaari |
| Sumitomo Pharma America, INC. | $15.00 | 2025 | Orgovyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.93 | 2021 | |
| Kyowa Kirin, INC. | $13.90 | 2023 | Poteligeo |
| Cti Biopharma Corp. | $13.42 | 2022 | |
| Adc Therapeutics America, INC. | $12.51 | 2022 | |
| Epizyme, INC. | $12.49 | 2021 | |
| Clovis Oncology, INC. | $12.31 | 2019 | |
| Puma Biotechnology, INC. | $11.34 | 2021 | |
| Secura Bio, INC. | $9.76 | 2019 |
Drugs and devices associated with these payments
Imbruvica $615Epkinly $509Enhertu $400Reblozyl $255Xtandi $245Kisqali $232Libtayo $218Ibrance $218Padcev $178Keytruda $172Opdivo $157Scemblix $157Orgovyx $154Trodelvy $147Ojjaara $136Injectafer $125Adcetris $120Ogsiveo $118Talzenna $116Jakafi $113Darzalex $109Elrexfio $109Fabhalta $107Ultomiris $106Stivarga $101Tecvayli $99.72Zepzelca $97.70Jevtana $96.82Clonoseq $92.86Pluvicto $90.46Welireg $88.11Opdualag $87.47Onivyde $84.02Bosulif $83.75Iclusig $82.97Imfinzi $82.92Vitrakvi $82.87Lenvima $79.84Nubeqa $78.23Erleada $77.99Venclexta $76.94Orserdu $71.40Xt Cdx $69.59Fotivda $67.67Besremi $66.57Braftovi $65.90Mektovi $65.90Comirnaty $65.58Xofigo $59.84Ayvakit $52.36Tivdak $49.27Cabometyx $48.27Lutathera $47.99Shingrix $44.90Lynparza $44.49Lumakras $40.30Promacta $40.16Enjaymo $39.52Paxlovid $37.92Polivy $35.86Pyrukynd $35.46Vectibix $34.53Besponsa $33.15Brukinsa $32.29Monoferric $32.18Zoladex $31.10Akeega $30.97Balversa $30.97Avastin $30.63Vyloy $30.37Piqray $30.13Lorbrena $29.73Xalkori $29.73Xermelo $28.56Rybrevant $28.47Inqovi $27.42Lonsurf $27.42Verzenio $26.81Retevmo $26.81Jaypirca $26.81Tepmetko $25.00Stimufend $24.65Tibsovo $24.13Pylarify $23.46Talvey $23.44Carvykti $23.44Augtyro $22.86Tevimbra $22.76Amtagvi $22.38Fruzaqla $21.60Wayrilz $21.25Xgeva $21.17Nplate $21.17Lunsumio $20.64Danziten $20.59Vivimusta $20.59Elzonris $19.56Xpovio $19.49Pedmark $19.28Rolvedon $18.92
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Kulkarni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.